Medical Oncologist
Hyderabad's Dedicated Lymphoma Panel
Best Lymphoma Doctors in Hyderabad — CION's Dedicated Lymphoma Panel
Lymphoma is one of the most treatable cancers — and also one of the most pathology-dependent. The WHO classification distinguishes more than 70 distinct lymphoma subtypes, each with different biology, prognosis, and treatment. CION operates Hyderabad's dedicated lymphoma panel across 11 locations — with Dr. Owais Mohammed (MRCP SCE, UK) leading medical-oncology chemotherapy delivery and Dr. Basudev Pokhrel leading hematology and the stem-cell transplant pathway. Hematopathology review is part of every case.
- Hematopathology review for every case — WHO 2022 subtyping with IHC, flow cytometry & molecular markers
- R-CHOP, ABVD & BV-AVD delivered in-house — standard regimens for B-cell NHL and Hodgkin per current NCCN
- PET-adapted treatment with interim PET-2 — response-adapted intensification or de-escalation after 2 cycles
- Stem cell transplant capability — autologous SCT for relapsed Hodgkin & aggressive NHL, led by Dr. Basudev Pokhrel
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The CION Lymphoma Panel
16 specialists, one team. Hematology- and chemo-led, tumour-board reviewed.
Lymphoma is treated by a coordinated team rather than a single specialty. Hematology and medical oncology lead — Dr. Owais Mohammed (MRCP UK) for chemotherapy delivery and Dr. Basudev Pokhrel for hematology and stem cell transplant. Radiation oncology is critical for combined-modality Hodgkin and bulky disease. Surgery's role is limited to the excisional biopsy that confirms diagnosis. Use the tabs to filter by specialty; request a specific doctor by name when booking.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Hematopathology review for every lymphoma case
Specialist hematopathology review with immunohistochemistry, flow cytometry, and molecular markers is part of every CION lymphoma case — critical for accurate WHO subtype classification across the 70+ recognised lymphoma subtypes. Treatment decisions are not finalised until subtyping is confirmed.
Specialist Disambiguation
Which Type of Doctor Actually Treats Lymphoma?
Lymphoma is treated by a coordinated team rather than a single specialty. Hematology and medical oncology are the lead specialties — hematologists particularly for stem cell transplant cases, medical oncologists for outpatient chemotherapy. Radiation oncology is critical for early-stage Hodgkin lymphoma and bulky disease consolidation. Surgery is used only for the excisional lymph node biopsy that confirms diagnosis — never for treatment.
The single most important specialty input is hematopathology — the pathology subspecialty that subtypes lymphomas through immunohistochemistry, flow cytometry, and molecular markers. Treatment decisions cannot be made without precise hematopathology classification.
| Specialist | What they treat | When you need them for lymphoma |
|---|---|---|
| General Physician | Common medical conditions — including initial workup of enlarged lymph nodes and B-symptoms | First-touch role for persistent lymph node enlargement, unexplained fever, night sweats, or weight loss. Should refer to hematology or oncology if cancer is suspected. |
| Hematologist | Blood and blood-forming organ diseases — including lymphoma, leukemia, and stem cell transplantation | Central specialist for lymphoma. Many lymphomas are managed by hematologists, particularly for stem cell transplant cases. CION's hematology and SCT pathway is led by Dr. Basudev Pokhrel. |
| Medical Oncologist | Systemic cancer treatment — chemotherapy, immunotherapy, targeted therapy | Delivers R-CHOP for B-cell NHL, ABVD or BV-AVD for Hodgkin lymphoma, R-Bendamustine for indolent NHL, immunotherapy (pembrolizumab, brentuximab vedotin), and CAR-T cell therapy coordination. |
| Radiation Oncologist | Radiation therapy — IMRT for involved-site radiation, consolidation radiation | Critical for Stage I–II Hodgkin lymphoma (combined modality with chemotherapy), bulky disease consolidation, and selected indolent NHL cases. Modern involved-site radiation (ISRT) replaces older wider-field approaches. |
| Surgical Oncologist (Biopsy Only) | Diagnostic biopsies — excisional lymph node biopsy | Performs the excisional lymph node biopsy that confirms lymphoma diagnosis. Surgery is NOT used to treat lymphoma — only for biopsy. Chemotherapy and radiation are the treatment modalities. |
| Pathologist (Hematopathology) | Tissue diagnosis — immunohistochemistry, flow cytometry, molecular markers | Critical for accurate lymphoma subtyping — WHO classification has 70+ lymphoma subtypes, each treated differently. Hematopathology subspecialty review essential before starting treatment. |
Which specialist should you see first?
Use this as a quick guide. Your specific situation may vary; any CION oncologist can review your case in 45 minutes and tell you which subspecialty should lead your care.
- Persistent enlarged lymph nodes (more than 4 weeks), unexplained fever, night sweats, weight lossEvaluation by physician with CBC, LDH, peripheral smear. If lymph nodes persist, excisional biopsy is essential.
- Biopsy confirms lymphomaDirect referral to hematology or medical oncology. Hematopathology review essential for subtyping. PET-CT for staging.
- Hodgkin lymphoma confirmedABVD chemotherapy (4–6 cycles depending on stage) or BV-AVD for selected high-risk cases. Combined modality with radiation for Stage I–II favourable.
- Aggressive B-cell NHL (DLBCL) confirmedR-CHOP chemoimmunotherapy (6–8 cycles). PET-2 after 2 cycles guides response. Pola-R-CHP for selected patients.
- Indolent NHL (follicular, marginal zone) confirmedWatch-and-wait for asymptomatic disease, or R-Bendamustine / R-CHOP / single-agent rituximab depending on burden.
- Relapsed or refractory diseaseSalvage chemotherapy, autologous stem cell transplant, and CAR-T cell therapy for eligible aggressive NHL.
The honest answer is that lymphoma almost always requires more than one specialist — but the lead is hematology and medical oncology, with hematopathology underpinning every decision.
Patient Decision Framework
Seven Questions to Ask Before You Choose a Lymphoma Doctor
Lymphoma diagnosis often arrives suddenly — after weeks of B-symptoms or an enlarged node finally biopsied. The questions below distinguish a centre that classifies lymphoma precisely and treats it appropriately from one that applies generic chemotherapy without adequate workup. Bring these seven questions to your first consultation — at CION, or anywhere else.
How many lymphoma cases does this team treat in a year — and which specialist will personally lead my case?
Lymphoma is rare enough that high-volume centres see meaningful differences from low-volume ones. Hematology + medical oncology depth, and hematopathology review quality, correlate with outcomes.
Is this Hodgkin lymphoma or Non-Hodgkin lymphoma — and what specific subtype?
These are different cancers with different protocols. Within NHL, the 70+ subtypes determine everything. A team that walks you through the precise WHO classification is one that takes pathology seriously.
Will my treatment be PET-adapted — and what is PET-2?
Interim PET-CT after 2 cycles of chemotherapy guides intensification or de-escalation. PET-adapted treatment improves outcomes in Hodgkin and aggressive NHL. A team that uses PET-2 explicitly is one current with modern lymphoma care.
Who will personally manage my case across chemotherapy, follow-up, and any salvage?
Lymphoma treatment runs months; follow-up runs years. Continuity matters — the doctor who knows your case across visits catches what matters.
Will I get a written cost estimate covering everything — before treatment starts?
Lymphoma treatment involves multiple PET scans, chemotherapy cycles, possible SCT. A centre that walks you through total cost in writing respects your circumstances.
How much time will I actually have to ask questions and understand my options?
Lymphoma decisions involve fertility, long-term toxicities, and response-adapted choices — none can be honestly unpacked in seven minutes.
Will my case be discussed by a team of specialists together?
Lymphoma decisions cut across hematology, medical oncology, radiation oncology, and hematopathology. No single doctor sees the full picture alone.
We mean it: take this list to any consultation — ours or anyone else's. A centre worth choosing will welcome them.
Our Standards, in Numbers
How CION Measures Up
Every standard below maps to a concern patients carry into their first consultation. We did not build these to look good on a webpage. We built them because they are what we would want if it were our family with the diagnosis.
Hodgkin vs Non-Hodgkin distinction at first consultation
These are very different cancers with different protocols — ABVD or BV-AVD for Hodgkin, R-CHOP and variants for Non-Hodgkin. The first job is precise classification.
R-CHOP and ABVD delivered in-house
The standard chemotherapy regimens for most B-cell NHL and Hodgkin lymphoma, with appropriate supportive care and infection prophylaxis.
PET-adapted treatment
Interim PET-CT after 2 cycles of chemotherapy (PET-2) guides treatment intensification or de-escalation — particularly for Hodgkin and aggressive NHL.
Stem cell transplant capability
Dr. Basudev Pokhrel leads our hematology and SCT pathway — autologous SCT for relapsed Hodgkin and aggressive NHL offered directly.
Hematopathology review for every case
WHO classification has 70+ lymphoma subtypes. Specialist hematopathology review with IHC, flow cytometry, and molecular markers is part of every CION lymphoma case.
Immunotherapy and targeted agents
Pembrolizumab and brentuximab vedotin for Hodgkin; obinutuzumab, polatuzumab, ibrutinib, and other targeted agents for NHL — per current NCCN guidelines.
Fertility preservation pathway
ABVD and R-CHOP can affect fertility. Sperm banking for men, oocyte preservation for women — coordinated with accredited reproductive medicine partners before treatment.
CAR-T cell therapy coordination
For relapsed/refractory aggressive NHL eligible for CAR-T, coordination with accredited CAR-T centres for evaluation and treatment.
Multidisciplinary tumour board for every case
Hematology, medical oncology, radiation oncology, and hematopathology — together — before any treatment decision.
One named lead specialist
From first consultation through chemotherapy, follow-up, and any salvage. No rotating juniors.
Written, itemised cost estimate
Chemotherapy, radiation, PET imaging, SCT if needed — quoted in writing before treatment begins.
Free written second opinion
Documented. Yours to keep. Take it to any doctor, anywhere — including our competitors.
Every number above is independently verifiable on request.
Operationally, Not in Marketing Language
How a Lymphoma Case Actually Moves Through CION
From your first call to your final follow-up, here is how your case moves through CION.
First Consultation (45 minutes)
A senior oncologist or hematologist reviews your case in full. If biopsy and imaging are available, we review what you have. Fertility preservation is introduced at this stage for reproductive-age patients. Family welcome. Telugu, Hindi, or English.
Hematopathology Review and Staging
Excisional lymph node biopsy (if not already done) confirms diagnosis. Hematopathology subtyping with IHC, flow cytometry, and molecular markers per WHO 2022 classification. PET-CT for staging. Bone marrow biopsy where indicated.
Multidisciplinary Tumour Board Discussion
Case presented to hematology, medical oncology, radiation oncology, and hematopathology — together. Consensus on subtype-specific protocol, number of cycles, PET-2 timing, and any combined-modality plan documented.
Treatment Plan with Named Lead Doctor
You meet your lead specialist. Full plan explained in your preferred language — protocol, cycles, expected side effects, fertility preservation, supportive care. Written, itemised cost estimate before anything begins.
Chemoimmunotherapy
Subtype-appropriate regimen — ABVD or BV-AVD for Hodgkin; R-CHOP for DLBCL; R-Bendamustine for indolent NHL. Pre-medications, growth factor support, infection prophylaxis as needed. Weekly review with your lead doctor.
Interim PET-2 and Response-Adapted Decisions
After 2 cycles, interim PET-CT assesses response. Treatment intensified, continued, or de-escalated based on Deauville score. For Hodgkin Stage I–II favourable, may transition to combined modality with radiation.
Follow-Up and Survivorship
End-of-treatment PET-CT confirms complete response. Clinical exam and imaging every 3 months for 2 years, then 6-monthly through year 5. Monitoring for late effects — secondary cancers, cardiac toxicity from anthracyclines, pulmonary toxicity from bleomycin. Survivorship clinic supports long-term care.
If at any stage you want a second opinion — internal or external — we facilitate it. Free, in writing, yours to keep.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Common questions
Frequently Asked Questions
Who is the best lymphoma doctor in Hyderabad?
The best doctor for lymphoma is a hematologist or medical oncologist with experience in lymphoma chemotherapy regimens (R-CHOP, ABVD, BV-AVD), paired with a radiation oncologist for combined-modality cases and a hematopathologist for precise subtype classification. At CION, every lymphoma case is reviewed by a multidisciplinary tumour board, with medical oncology led by Dr. Owais Mohammed (MRCP SCE UK) and hematology and SCT led by Dr. Basudev Pokhrel.
Is this Hodgkin lymphoma or Non-Hodgkin lymphoma — and how does that change treatment?
Hodgkin lymphoma and Non-Hodgkin lymphoma are very different cancers. Hodgkin lymphoma is characterised by Reed-Sternberg cells on pathology, typically affects young adults (peak ages 20–40), often presents in cervical or mediastinal lymph nodes, and is treated with ABVD chemotherapy (or BV-AVD for high-risk cases) — cure rates exceed 85% for early-stage disease. Non-Hodgkin lymphoma is an umbrella term for 70+ subtypes, treated very differently depending on the specific type — aggressive B-cell NHL like DLBCL uses R-CHOP, indolent follicular NHL may use watch-and-wait or R-Bendamustine, T-cell NHL uses CHOEP or specialised protocols. The first job of the pathologist and tumour board is to establish which lymphoma you have.
What is PET-adapted treatment for lymphoma?
PET-adapted treatment uses interim PET-CT scans during chemotherapy to guide treatment intensity. The most established example is PET-2 in Hodgkin lymphoma — a PET scan after 2 cycles of ABVD. Patients with negative PET-2 may have bleomycin omitted (reducing lung toxicity) or fewer total cycles; patients with positive PET-2 may have treatment intensified to escalated BEACOPP. PET-2 is also used in aggressive NHL to identify early non-responders for treatment change. CION's pathway includes interim PET-2 review for Hodgkin lymphoma and aggressive NHL.
What is R-CHOP — and is it offered here?
R-CHOP is the standard chemotherapy regimen for diffuse large B-cell lymphoma (DLBCL) — the most common aggressive Non-Hodgkin lymphoma. It combines rituximab (an anti-CD20 antibody) with cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone — given in 21-day cycles, typically 6–8 cycles. R-CHOP achieves cure in 60–70% of patients with DLBCL. Newer regimens (Pola-R-CHP, R-mini-CHOP, R-EPOCH for certain subtypes) may be used in selected cases. CION delivers R-CHOP and its variants per current NCCN guidelines.
What is ABVD — and is it offered here?
ABVD is the standard chemotherapy regimen for Hodgkin lymphoma — adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine. Given in 28-day cycles, typically 2–6 cycles depending on stage and risk. Combined with radiation for Stage I-II favourable disease. ABVD-based regimens cure over 85% of Hodgkin lymphoma patients. BV-AVD (brentuximab vedotin + AVD, omitting bleomycin) is used in advanced-stage high-risk disease per ECHELON-1 evidence. CION delivers ABVD and BV-AVD per current NCCN guidelines.
Can my fertility be preserved before lymphoma treatment?
Yes — ABVD, R-CHOP, and especially BEACOPP can affect fertility, more so in women than in men. Sperm banking before treatment is standard of care for reproductive-age men. Oocyte cryopreservation or ovarian tissue cryopreservation may be considered for women — though urgency of treatment sometimes limits options. CION coordinates fertility preservation with accredited reproductive medicine partners. The fertility conversation is part of the first consultation.
What is stem cell transplant for lymphoma?
Stem cell transplant (autologous SCT — using the patient's own stem cells) is used for relapsed Hodgkin lymphoma after first-line therapy, relapsed aggressive NHL responding to salvage chemotherapy, and selected high-risk first-line cases. It involves high-dose chemotherapy followed by stem cell rescue. Allogeneic SCT (using donor cells) is used less commonly, typically for highly refractory disease. CION provides stem cell transplant capability led by Dr. Basudev Pokhrel.
What is CAR-T cell therapy and am I eligible?
CAR-T cell therapy genetically modifies the patient's own T cells to attack CD19-expressing B-cell lymphomas. It is approved for relapsed/refractory aggressive B-cell NHL (DLBCL, primary mediastinal B-cell, transformed follicular) and a few other indications. CAR-T is delivered at specialised CAR-T centres after careful patient selection. CION coordinates CAR-T evaluation with accredited CAR-T centres for eligible patients. Cost remains high and access is limited but improving.
How do I get a second opinion for lymphoma in Hyderabad?
A second opinion is especially valuable for lymphoma — both because subtype classification can vary across pathologists and because PET-adapted treatment decisions vary across centres. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your biopsy, pathology, imaging, and existing recommendation and provides a documented opinion you can take anywhere.
How much does lymphoma treatment cost in Hyderabad?
Costs vary widely by lymphoma type and treatment intensity. Hodgkin lymphoma treatment (full ABVD plus PET imaging) ranges approximately ₹4,00,000 to ₹8,00,000. R-CHOP for DLBCL (6 cycles plus PET scans) ranges ₹6,00,000 to ₹12,00,000+. BV-AVD or Pola-R-CHP are significantly higher. Autologous stem cell transplant adds ₹12,00,000 to ₹20,00,000+. CAR-T cell therapy is significantly higher again. For a detailed cost breakdown, see our lymphoma treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate before treatment. Aarogyasri, EMI, and cashless insurance accepted.
Take the next step with a team that does this every day
Hodgkin and Non-Hodgkin protocols delivered in-house. Hematopathology review for every case. PET-adapted treatment. Stem cell transplant capability. Fertility preservation pathway. CAR-T coordination for eligible cases. Multidisciplinary tumour board. Free 45-minute consultation. NABH-accredited. Aarogyasri, EMI, and cashless insurance accepted.
This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist or hematologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.